ANGLE Announces Positive Interim Evaluation of Ovarian Cancer Clinical Studies

ANGLE Announces Positive Interim Evaluation of Ovarian Cancer Clinical Studies
ANGLE has completed the planned interim analysis of two clinical studies, in Europe and the United States, evaluating its Parsortix system in women with ovarian cancer. The data has shown that the system can accurately distinguish malignant masses from benign tumors. Parsortix is ANGLE’s specialized platform technology that captures tumor cells circulating in blood — even when they are as

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *